Accuray has signed a memorandum of understanding (MOU) with the University of Wisconsin-Madison to advance online adaptive radiotherapy using the company’s helical radiation treatment delivery technology.
The MOU outlines intentions among Accuray and the school’s Department of Human Oncology to collaborate on clinical research, education and training, and adaptive technology development to improve cancer care, the company said.
UW-Madison researchers invented the first helical radiation delivery platform, TomoTherapy, and sold it to Accuray in 2011. Since then, Accuray has continued to evolve the helical platform with the purpose of further enhancing its precision and accuracy, according to the firm.
